References
- 1. Cusa BV, Sagud M, Rados I. The role of dehydroepiandrosterone (DHEA) in schizophrenia. Psychiatr Danub. 2016; 28(1): 30-3.
- 2. Misiak B, Piotrowski P, Chec M, et al. Cortisol and dehydroepiandrosterone sulfate in patients with schizophrenia spectrum disorders with respect to cognitive performance. Compr Psychoneuroendocrinol. 2021; 6. Available from: https://dou.org/10.1016/j.cpnec.2021.10004110.1016/j.cpnec.2021.100041
- 3. Nuechterlein KH, Dawson ME, Ventura J, et al. The vulnerability/stress model of schizophrenic relapse: a longitudinal study. Acta Psychiatr Scand. 1994; 89: 58-64.10.1111/j.1600-0447.1994.tb05867.x
- 4. Piotrowski P, Rymaszewska J, Stanczykiewicz B, et al. Stress coping strategies and their clinical correlates in patients with psychosis at various stages of illness: a case-control study. Early Interv Psychiatr. 2019; 4: 559-67.
- 5. Wambua GN, Kilian S, Ntlantsana V, et al. The association between resilience and psychosocial functioning in schizophrenia: a systematic review and meta-analysis. Psychiatr Res. 2020; 293:113374. 10.1016/j.psychres.2020.11337410.1016/j.psychres.2020.113374
- 6. Gallagher P, Ritsner MS. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes: Metabolic and Peripheral Biomarkers. Can the Cortisol to DHEA Molar Ratio be Used as a Peripheral Biomarker for Schizophrenia and Mood Disorders? Springer. 2009; pp.27-45.10.1007/978-1-4020-9838-3_3
- 7. Morfin R. DHEA and the brain. Taylor and Francis, London and New York. 2002.10.1201/b12558
- 8. Baulieu EE, Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neuro-steroids. J Endocrinol. 1996; 150:221-39.
- 9. Maninger N, Wolkowitz OM, Reus VI, et al. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA Sulfate (DHEAS). Front Neuroendocrinol. 2009; 30(1):65-91.10.1016/j.yfrne.2008.11.002
- 10. Wen S, Dong K, Onolfo JP, et al. Treatment with dehydroepiandrosterone sulfate increases NMDA receptor in hippocampus and cortex. Eur J Pharmacol. 2001; 430:373-4.10.1016/S0014-2999(01)01383-8
- 11. Compagnone NA, Melton SH. Neurosteroids: biosynthesis and function of these novel neuro-modulators. Front Neuroendocrinol. 2000; 21:1-56.10.1006/frne.1999.018810662535
- 12. Singh M, Solanki RK, Bagaria B, et al. Hypothalamic-pituitary-adrenal (HPA) axis functioning among patients with schizophrenia: A cross sectional comparative study. J Psychiatry. 2015; 18(1):14-65.
- 13. Erjavec G, Uzun S, Perkovic M, et al. Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 77:228-35.10.1016/j.pnpbp.2017.04.03228461252
- 14. di Michele F, Caltagirone C, Bonaviri G, et al. Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. J Psychiatr Res. 2005; 39:267-73.10.1016/j.jpsychires.2004.08.00515725425
- 15. Strous RD, Maayan R, Lapidus R, et al. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr Res. 2004; 71:427-34.10.1016/j.schres.2004.03.00515474914
- 16. Ritsner M, Maayan R, Gibel A, et al. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol. 2004; 14:267-73.10.1016/j.euroneuro.2003.09.00315163435
- 17. Misiak B, Stramecki F, Gaweda L, et al. Interactions between variation in candidate genes and environmental factors in the etiology of schizophrenia and bipolar disorder: a systematic review. Mol Neurobiol. 2018; 55(6): 5075-100.10.1007/s12035-017-0708-y594825728822116
- 18. Zhang XY, Zhou DF, Cao LY, et al. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacol. 2005; 30(8):1532-8.10.1038/sj.npp.130075615886721
- 19. Gorobets LN, Litvinov AV, Bulanov VS. The indices of cortisol and dehydroepiandrosterone sulfate as potential biomarkers of the efficacy of antipsychotic therapy in patients with the first psychotic episode. Современная терапия психических расстройств. 2018; 1:11-19.
- 20. Mondelli V, Ciufolini S, Murri MB, et al. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophrenia Bull. 2015; 41(5):1162-70.10.1093/schbul/sbv028453563725829375
- 21. Yıldırım O, Dogan O, Semiz M, et al. Serum cortisol and dehydroepiandrosterone-sulfate levels in schizophrenic patients and their first-degree relatives. Psychiatry Clin Neurosci. 2011; 65:584–91.10.1111/j.1440-1819.2011.02252.x21895860
- 22. Ryan MC, Sharifi N, Condren R, et al. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrino. 2004; 29:1065-70.10.1016/j.psyneuen.2003.08.01115219658
- 23. Gallagher P, Watson S, Smith MS, et al. Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophr Res. 2007; 90(1-3): 258-65.10.1016/j.schres.2006.11.02017222537
- 24. Hori H, Teraishi T, Sasayama D, et al. Elevated cortisol level and cortisol/DHEAS ratio in schizophrenia as revealed by low-dose dexamethasone suppression test. The Open Neuropsychopharmacology. 2012; 5:18-24.10.2174/1876523801205010018
- 25. Venkatasubramanian G, Chittiprol S, Neelakantachar N, et al. Effect of antipsychotic treatment on Insulin-like Growth Factor-1 and cortisol in schizophrenia: a longitudinal study. Schizophr Res. 2010; 119(1-3):131-7.10.1016/j.schres.2010.01.03320226630
- 26. Yilmaz N, Herken H, Cicek HK, et al. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med Princ Pract. 2007; 16(2):137-41.10.1159/000098367
- 27. Boiko AS, Mednova IA, Kornetova EG, et al. Cortisol and DHEAS related to metabolic syndrome in patients with schizophrenia. Neuro-psych Dis Treat. 2020; 16:1051-8.10.2147/NDT.S247161
- 28. Bulut SD, Bulut S, Gundogmus AG, et al. Serum DHEA-S, testosterone and cortisol levels in female patients with schizophenia. Endocr Metab Immune Disord Drug Targets. 2018; 18(4):348-54.10.2174/1871530318666180212102128
- 29. Kaneda Y, Fujii A, Ohmori T. The hypothalamic-pituitary adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26:935–8.10.1016/S0278-5846(02)00208-7
- 30. Taherianfard M, Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients. Indian J Med Sci. 2004; 58(1):3-9.
- 31. Wilczynski KM, Tobolska D, Lorek M, et al. Comparison of cortisol levels in patients with schizophrenia and in healthy controls. Eur Psychiat. 2017; 41:818.10.1016/j.eurpsy.2017.01.1593
- 32. Meltzer HY, Lee MA, Jayathilake K. The blunted plasma cortisol response in patients with schizophrenia. Neuropsychopharmacol. 2001; 24:278-90.10.1016/S0893-133X(00)00201-3
- 33. Misiak B, Frydecka D, Oska O, et al. Testosterone, DHEA and DHEA-S in patients with schizophrenia: A systematic review and meta-analysis. Psychoneuroendocrino. 2018; 89: 92-102.10.1016/j.psyneuen.2018.01.00729334627
- 34. Beyazyüz M, Albayrak Y, Beyazyüz E, et al. Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia. Neuropsychiatr Dis Treat. 2014; 10: 687–93.
- 35. Solanki RK, Sharma P, Tyagi A, et al. Serum levels of neuroactive steroids in first-episode antipsychotic-naïve schizophrenic patients and its correlation with aggression: a case-control study. East Asian Arch Psychiatry. 2017; 27:79-84.
- 36. Ji E, Weickert CS, Tyson TP, et al. Cortisol-dehydroepiandrosterone ratios are inversely associated with hippocampal and prefrontal brain volume in schizophrenia. Psychoneuroendrocrinol. 2021; 123:104916.10.1016/j.psyneuen.2020.10491633169678
- 37. Ritsner M, Gibel A, Ram E, et al. Alterations in DHEA metabolism in schizophrenia: Two-month case-control study. Eur Neuropsychopharmacol. 2006; 16:137-46.10.1016/j.euroneuro.2005.07.00716139994
- 38. Ritsner M, Gibel A, Maayan R, et al. Cortisol/ Dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacol. 2005; 30:1913-22.10.1038/sj.npp.130074715870835
- 39. Peng R, Li Y. Association among serum cortisol, dehydroepiandrosterone-sulfate levels and psychiatric symptoms in men with chronic schizophrenia. Compr Psychiatry. 2017; 76:113-8.10.1016/j.comppsych.2017.03.01128482249